http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-061825-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57563 |
| filingDate | 2007-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b279de9d207006098a1859308fbf005b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11ffe0272c80ee1827f7472361f8c8bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6447a3d6c5640b7b1aadbd6c104bd0e4 |
| publicationDate | 2008-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-061825-A1 |
| titleOfInvention | ANALOGS OF THE VASOACTIVE INTESTINAL PEPTIDE (VIP) |
| abstract | For the treatment of obstructive pulmonary diseases, for example COPD, administered, for example, by inhalation. Claim 1: A cyclic analog of the vasoactive intestinal peptide of formula (1) X-His-R2-Asp-Ala-R5- Phe-Thr-Glu- Asn-Tyr-Thr-Lys-Leu-Arg-Lys-R16-Nle -R18-Ala-Lys-Lys21-Tyr-Leu-Asn-Asp25-Leu-R27-R28-Gly-Gly-Thr-Y [X- (Sec. ID No.: 2) -Y] in which X is an H of the N-terminal amino of Histidine which may be optionally substituted by a hydrolysable amino protecting group, more preferably by an acetyl group, Y is the C-terminal carboxyl hydroxyl of Threonine that may be optionally substituted by a hydrolysable carboxyl protecting group, more preferably by NH2, the underlined residues indicate a covalent side chain to side chain linkage of the first amino acid (Lys21) and the last (Asp25) within the segment, R2 is Ser or Ala, R5 is Thr, Ser , Asp, Gln, Pro or CalfaMeVal, R16 is Gln, Ala or Arg, R18 is Ala, Lys or Glu, R27 is Lys or Leu with the exception that R27 must be Lys when R5 is CalfaMeVal and R16 is Arg, R28 is Lys or Asn, or a salt far pharmaceutically acceptable thereof. |
| priorityDate | 2006-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.